# Rifaximin in Fatty Liver Disease

> **NCT01355575** · PHASE4 · TERMINATED · sponsor: **Imperial College London** · enrollment: 15 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease
- NAFLD
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT01355575
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Primary endpoint data review concluded no further patients required.
- **Last updated:** 2020-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355575, "Rifaximin in Fatty Liver Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01355575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*